Gabriella Katana
Chandler, AZNPI 1508331356
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 335 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations.
Across 335 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$631
- Novo Nordisk$493
- Pfizer$373
- Sanofi-aventis U.S. LLC$352
- Abbott$289
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,465100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 98 | $1,113 |
| GSK | 35 | $631 |
| Novo Nordisk | 32 | $493 |
| Pfizer | 22 | $373 |
| Sanofi-aventis U.S. LLC | 18 | $352 |
| Abbott | 14 | $289 |
| Amgen | 17 | $238 |
| Lucid Diagnostics Inc. | 3 | $186 |
| Boehringer Ingelheim | 9 | $178 |
| Merck | 9 | $161 |
| Lilly USA, LLC | 10 | $150 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $126 |
| Medtronic | 6 | $118 |
| Bayer | 6 | $117 |
| Biohaven Pharmaceuticals, Inc. | 7 | $112 |
| Sumitomo Pharma America, Inc. | 4 | $96 |
| AstraZeneca | 6 | $89 |
| Exact Sciences | 4 | $87 |
| Astellas Pharma US Inc | 3 | $68 |
| Dexcom, Inc. | 3 | $68 |
| Boston Scientific | 3 | $64 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $47 |
| Insulet Corporation | 2 | $37 |
| Eisai Inc. | 2 | $35 |
| Novartis | 1 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $25 |
| Gilead | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Phadia US Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Seqirus USA Inc | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 38 | $55,610 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 43 | $53,040 |
| EliquisApixaban | 47 | $44,746 |
| OzempicSemaglutide | 27 | $31,111 |
| TrulicityDulaglutide | 12 | $27,110 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $22,713 |
| XareltoRivaroxaban | 11 | $17,636 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $13,784 |
| MyrbetriqMirabegron | 20 | $13,198 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 79 | $2,832 |
| Atorvastatin Calcium | 337 | $2,756 |
| Levothyroxine Sodium | 234 | $2,229 |
| Wixela InhubFluticasone Propion/Salmeterol | 18 | $2,040 |
| NovologInsulin Aspart | 15 | $1,934 |
| Gabapentin | 76 | $1,715 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $178 | $55,61038 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $352 | $53,04043 claims |
| PfizerEliquis | $373 | $44,74647 claims |
| Novo NordiskOzempic, Novolog | $493 | $33,04542 claims |
| Lilly USA, LLCTrulicity | $150 | $27,11012 claims |
| GSKTrelegy Ellipta | $631 | $22,71318 claims |
| Astellas Pharma US IncMyrbetriq | $68 | $13,19820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Arizonaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.